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Abstract Nephrogenic systemic fibrosis (NSF) is a rela-
tively new entity, first described in 1997. Few cases have
been reported, but the disease has high morbidity and
mortality. To date it has been seen exclusively in patients
with renal dysfunction. There is an emerging link with
intravenous injection of gadolinium contrast agents, which
has been suggested as a main triggering factor, with a lag
time of days to weeks. Risk factors include the severity of
renal impairment, major surgery, vascular events and other
proinflammatory conditions. There is no reason to believe
that children have an altered risk compared to the adult
population. It is important that the paediatric radiologist
acknowledges emerging information on NSF but at the
same time considers the risk:benefit ratio prior to embark-
ing on alternative investigations, as children with chronic
kidney disease require high-quality diagnostic imaging.
Keywords Nephrogenicsystemicfibrosis.Gadolinium.
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Introduction
Nephrogenic systemic fibrosis (NSF; formerly named
nephrogenic fibrosing dermopathy) is a systemic disease
that was first described in 1997 and recognized as a
separate clinical entity in 2000 [1–4]. Until now, all
confirmed cases of NSF have been reported in patients
with chronic kidney disease (CKD) with estimated glomer-
ular filtration rates (eGFR) <60 ml/min per 1.73 m
2 or end-
stage renal failure requiring renal replacement therapy. NSF
affects both sexes with a reported age range of 8–87 years
and has no race predilection [5, 6]. Relatively few
paediatric cases have been reported, which may reflect the
lower incidence of CKD in children.
Patients present with swelling, induration and tightening
of the skin, often with a peau d’orange appearance or
textured plaques, papules or nodules, usually limited to the
extremities (from ankles to mid-thighs and from wrists to
mid-upper arms). The skin lesions sometimes involve the
trunk, but spare the neck and face. The condition develops
over days to weeks and may ultimately result in severe
contractures and disability. Patients may experience burn-
ing, itching or sharp pains in involved areas. Deep pain has
also been described in the hips and ribs. Radiography may
reveal calcifications of the soft tissue [1, 5–9]. Systemic
involvement may be fatal with fibrosis of the lungs, skeletal
muscles, pleura, pericardium, myocardium, kidneys, mus-
cle, bone, testes and dura [2–4, 10]. Clinical differential
diagnoses include scleroderma, scleromyxoedema, systemic
sclerosis/morphoea, eosinophilic fasciitis and eosinophilia-
myalgia syndrome, and the condition may mimic cellulitis,
panniculitis or drug reactions [6–8, 11, 12].
The severity of CKD appears to be the main determinant
of risk. Also, several contributing risk factors have been
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diomyopathy; hepatic disease; idiopathic pulmonary fibro-
sis; systemic lupus erythematosus; brain tumours; recent
surgical procedures, especially those with a major vascular
component; and other proinflammatory conditions, includ-
ing liver transplantation [5, 6, 8, 13, 14].
A specific aetiology is still unknown. The only common
factor in all patients is the underlying kidney disease, with
most patients dialysis-dependent. However, NSF has also
been reported in patients who have never been dialysed [1,
5, 6, 8]. The physiopathological mechanism for fibrosis is
not yet known. Histopathologically, biopsies from the skin
lesions show a proliferation of fibrocytes (which may
extend into subcutaneous tissue), together with thick
collagen bundles and surrounding clefts with a variable
amount of mucin and elastic fibres. Fibrocytes have a
specific immunophenotype and express CD34, CD11b,
CD45, HLA-DR, CD71, CD80, CD86, which implies that
they are recruited from the circulation and do not arise as a
result of proliferation in situ. Inflammatory cells are not
usually evident, although small clusters of perivascular
mononuclear cells may be seen [11, 15, 16].
Therapeutic options in NSF are limited. Improvements
have been reported with extracorporeal photopheresis,
plasmapheresis, ultraviolet phototherapy, intravenous im-
munoglobulin and renal transplantation [17–21].
Link with gadolinium-based contrast agents
The main concern for the radiologist is a growing body of
evidence that clinical use of gadolinium-based contrast
agents may trigger the disease. A number of patients with
NSF seem not to have had any previous gadolinium
exposure, but these are still under investigation. Grobner
[22] was the first to report this association in January 2006.
Grobner described nine patients with end-stage renal failure
on dialysis who underwent MR angiography (MRA) with
gadodiamide (Omniscan; GE Healthcare, Chalfont St Giles,
UK); five (mean age 57.2±10.7 years) developed NSF after
2–4 weeks. All patients who developed NSF had confirmed
metabolic acidosis, whilst all patients who did not develop
NSF had normal pH and bicarbonate level at the time of the
MRA. The average contrast agent volume used was 35 ml.
Marckmann et al. [23] reviewed case notes from their
own nephrology department from August 2005 to May
2006 and found 13 patients with confirmed NSF, all
exposed to gadodiamide. All patients were adults (33–
66 years of age, mean 50 years), developed NSF 2–75 days
(mean 25 days) after gadolinium exposure and had an
eGFR <8 ml/min. From this cohort of renal patients the
authors estimated an odds ratio between 32.5 and 47.6 for
developing NSF following gadolinium exposure.
The link between gadolinium exposure and NSF has
been further strengthened by two reports of gadolinium
deposits in tissue samples of patients with NSF. High et al.
[24] detected gadolinium in 4 out of 13 skin and soft-tissue
biopsies from seven patients with documented NSF. All
patients with NSF received gadolinium-based contrast
medium prior to disease and the interval between dosing
and biopsy could be determined with certainty only for two
of four patients (age range 4–11 months). The same group
reported in a research letter following quantitative analysis
of the four tissue samples in which gadolinium was
detected that the amount of gadolinium in the affected
tissue of patients with NSF was approximately 35- to 150-
fold the level of gadolinium in the bone of healthy
volunteers with normal renal function. In a case report,
Boyd et al. [25] found gadolinium deposits in areas of
calcium phosphate deposition in blood vessels in a 68-year-
old patient with NSF who had been previously exposed to
gadodiamide.
Sadowski et al. [26] retrospectively reviewed data from
13 patients with confirmed NSF (eight males, five females,
age 17–69 years), all exposed to gadodiamide. The median
time between onset of NSF symptoms and last contrast-
enhanced MRI examination was 11.5 days. The dose of
contrast agent administered varied from 0.1 to 0.31 mmol/kg
(actual) body weight. At the time of the contrast-enhanced
MRI all 13 patients had CKD (eGFR <60 ml/min per
1.73 m
2) and were hospitalized for a proinflammatory
event (major surgery, infection or vascular event). The
group with NSF had significantly lower eGFR, more
proinflammatory events, and more contrast-enhanced MR
examinations per patient (P<0.002) than did the control
group. The incidence of NSF in this study and institution
was 4.6% per year.
A review of six further NSF cases that were also related
in time to gadodiamide administration has recently been
published [27]. Patients were aged 23–71 years and the
onset of symptoms consistent with NSF was between
19 days and 2 months after gadodiamide exposure. All
patients had severe renal failure and were exposed to a
gadodiamide dose ranging from 0.11 to 0.36 mmol/kg body
weight. Despite having normal serum bicarbonate, five of
the six patients had an elevated anion gap metabolic
acidosis.
Broome et al. [28] have recently reported a retrospective
study of 12 patients with NSF, all of whom received a
double dose (0.2 mmol/kg body weight) of gadodiamide 2–
11 weeks before the development of skin fibrosis. This
group included eight men and four women (age 26–
64 years) and all had renal insufficiency at the time of
gadodiamide administration. The odds ratio for develop-
ment of NSF in the gadodiamide-exposed patients com-
pared with the gadodiamide-unexposed patients was 22.3
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dialysis patients was 4.0%. The odds ratio for development
of NSF with double-dose compared to single-dose gado-
diamide administration was 12.1. Ten patients were
dialysed within 2 days of gadodiamide administration, but
this failed to prevent the development of NSF.
Although the overwhelming majority (around 90%) of
patients with gadolinium-associated NSF had been exposed
to gadodiamide, there are now several reports of exposure
to other gadolinium contrast agents. In a recent editorial in
Radiology, Kuo et al. [29] reported 57 patients with NSF
investigated by the United States Food and Drug Adminis-
tration (FDA). In 43 of these the NSF was linked to gado-
diamide; in 6 to gadopentetate dimeglumine (Magnevist;
Berlex Imaging, Montville, N.J.); in 2 to gadoversetamide
(OptiMARK; Mallinckrodt, St. Louis, Mo.); and in 3 to
gadodiamide plus gadoversetamide; in 3 other patients, the
associated specific gadolinium-based MR contrast agent
was not definitively identified. Sadowski et al. [26] also
reported one patient with confirmed NSF associated with
both gadodiamide and gadobenate dimeglumine (Multi-
Hance, Bracco Diagnostics, Milan, Italy). NSF related to
specific gadolinium-based contrast agents is also monitored
by the manufacturers, who have recently published several
reports [30–32]. In a retrospective study in Scotland of
1,826 haemodialysis patients, Collidge et al. [33] found a
positive association between the cumulative dose of
gadodiamide and the development of NSF. Patients who
developed NSF had received a higher median cumulative
dose of gadodiamide (0.39 mmol/kg vs. 0.23 mmol/kg in
patients without NSF).
A case-control study by Marckmann et al. [34] con-
ducted in 19 patients with histologically verified NSF and
19 matched controls found that increasing cumulative
gadodiamide exposure, high-dose epoietin-b treatment and
higher serum concentrations of ionized calcium and
phosphate increase the risk of gadodiamide-related NSF in
patients with renal failure.
Pathophysiology
Although not completely understood, several factors are
known to contribute to the physiopathological mechanism
in NSF. Gadolinium chelates are mostly eliminated through
the kidneys. Renal impairment will therefore prolong the
presence of these agents in the body, facilitating the release
of the toxic free gadolinium ion (Gd
3+) by dissociation
from its chelate (chemical imbalance, acidosis, anion gap,
inflammation) and its subsequent binding to endogenous
ions. This chemical process, known as transmetallation,
may be promoted by acidosis and anion gap, e.g. under
inflammatory conditions [35–40]. It has therefore been
suggested that both the chemical stability of a particular
chelate (cyclic compounds are more stable than linear ones
in vitro) and the dose administered are risk factors for
triggering NSF [28, 41]. Once released Gd
3+ forms
hydroxides and phosphates (insoluble at a pH >6.2) and
these are probably engulfed by phagocytic cells [42]. This
might affect the reticuloendothelial system, inhibiting the
activity of certain enzymes with consequent foreign body
and fibrous reactions [41, 43–45]. Gadodiamide, the agent
involved in NSF in most patients to date, is the least stable
in terms of susceptibility to transmetallation in vitro, being
an open-chain compound [46]. Free gadolinium ions may
remain in the body for weeks to months, allowing more
time for toxic effects [47]. Gadolinium is a well-known
inorganic calcium channel blocker and its acute toxicity
may also partly be explained via this mechanism [48, 49].
A review of the properties of commercial gadolinium con-
trast agents and their relation to NSF is presented in Table 1.
NSF in children
NSF in children has also been reported. Five patients under
18 years of age have thus far been reported (discussed be-
low) out of a total of ten in the central database of the Inter-
national Center for Nephrogenic Fibrosing Dermopathy
Research (Dr. S. Cowper, personal communication). How-
ever, 13 possible patients have been reported to an online
paediatric nephrology forum in June 2007 (https://listhost.
uchicago.edu/mailman/private/pedneph/) and these are still
being investigated in relation to previous gadolinium
exposure.
In 2003 Jan et al. [50] reported two paediatric patients
with nephrogenic fibrosing dermopathy: a 16-year-old
female patient with a life-long history of kidney failure
and an 8-year-old boy with a 9-month history of mem-
branoproliferative glomerulonephritis type II. Both patients
had the clinical and histopathological features of NSF and
no contrast-enhanced MRI procedures were known to be
associated with these patients. However, this was before the
publication of a possible link with gadolinium.
Jain et al. [51] reported two more patients with NSF in
2004: a 9-year-old boy on peritoneal dialysis and a 19-year-
old male on haemodialysis with a 10-year history of
previous failed renal transplants, both diagnosed with NSF
on skin biopsies. The 9-year-old boy had a solitary MRA
performed in June 2002, approximately 2 months prior to
development of NFD. The history of the 19-year-old male
was more complicated as he underwent 13 separate MRA
procedures, all with gadolinium contrast agents, between
April 2000 and August 2004. At least nine of the MRAs
were performed prior to the NFD diagnosis in January 2003
[52]. Also, both patients had persistent metabolic acidosis
Pediatr Radiol (2008) 38:489–496 491T
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492 Pediatr Radiol (2008) 38:489–496in the months preceding the development of NSF, which
may have been a contributing factor [22].
DiCarlo et al. [53] described another patient with
histopathologically proven NSF. This patient was a 17-
year-old male renal transplant recipient (15 years following
transplant) who had recently begun peritoneal dialysis due
to graft failure. No relationship to MRI investigations was
mentioned.
Recently, Auron et al. [54] reported two patients with
NSF. One of the patients was a 13-year-old boy previously
reported at the age of 8 years by Jan et al. [50] in 2003
(discussed above). The second patient was a 20-year-old
male who at the age 14 years was diagnosed with acute
monoblastic leukaemia and 2 years later underwent bone
marrow transplant and later developed kidney failure. No
references to contrast-enhanced MRI are available from
these reports.
Our own hospital has a large paediatric renal unit with
up to 30 renal transplants per year. We have actively used
MRI both for concurrent conditions and complications to
CKD, as well as for providing a presurgical vascular road-
map, using contrast-enhanced MRA (Gd-DTPA, Magnevist,
Schering, Germany, 0.1–0.3 mmol/kg, i.v.). A review of all
contrast-enhanced scans in children referred via our
nephrology service (March 2002 to March 2007) showed
that 75 nephrology patients (neonate to 18 years of age;
median 9.6 years) had had 93 MRI scans with a follow-up
of at least 6 months. There were no patients with NSF in
this high-risk cohort.
Regulatory advice
Regulatory advice can be obtained from the websites listed
in Table 2. The FDA has issued a general warning for all
gadolinium-based contrast agents and advise against their
use in patients with eGFR <30 ml/min per 1.73 m
2 and in
all patients with acute renal insufficiency “unless the
diagnostic information is essential and not available with
non-contrast enhanced magnetic resonance imaging”.A t
the FDA’s request the manufacturers of gadolinium-based
contrast agents have revised the product labels, which now
include a new boxed warning and a new warnings section
that describes the risk of NSF. The European Medicines
Agency has so far not published any update of general
contraindications, and is not in a position to do so since all
but one gadolinium-based agent are licensed by individual
member states’ regulatory bodies. However, the issue was
discussed at a meeting of its pharmacovigilance group in
June and May 2007, and issued specific advice as follows
(http://www.mhra.gov.uk):
The use of Omniscan® and Magnevist® is contra-
indicated in patients with severe renal impairment (i.e.
GFR or eGFR <30 mL/min/1·73 m
2). Omniscan is
also contraindicated in patients with renal dysfunction
who have had, or who are awaiting, liver transplanta-
tion. For patients with moderate renal impairment
(GFR or eGFR 30–59 ml/min/1·73 m
2) or neonates
and infants up to 1 year of age, Omniscan and
Magnevist should be used only after careful consider-
ation. All patients should be screened for renal
dysfunction by obtaining a history and/or laboratory
tests, especially before Omniscan or Magnevist are
used. Haemodialysis shortly after administration of a
gadolinium-containing MRI contrast agent in patients
currently under haemodialysis may be useful for
removal of contrast agent from the body. However,
there is no evidence to suggest that haemodialysis can
prevent or treat development of NSF. Careful consid-
eration should also be given to the use of the other
gadolinium-containing MRI contrast agents in patients
with severe renal impairment.
Consequences for paediatric practice
There is an associated high morbidity and mortality with
CKD, and imaging aids clinical management, such as
assessment of secondary vasculopathies, infections etc, and
surgical planning prior to renal transplantation. Patients at
risk also include children with known or suspected CKD, as
well as newborns and infants with renal immaturity or
Table 2 Websites for regulatory updates and for information and registration of cases (accessed on 20 September 2007)
Organization Information provided URL
European Medicines Agency Regulatory information http://www.emea.europa.eu/
US Food and Drug Administration Regulatory information http://www.fda.gov/cder/drug/infopage/
gcca/default.htm
Information for healthcare professionals http://www.fda.gov/cder/drug/InfoSheets/
HCP/gcca_200705.htm
International Center for Nephrogenic Fibrosing
Dermopathy Research
Updated information and contact details for
registration of cases
http://www.icnfdr.org/
Pediatr Radiol (2008) 38:489–496 493congenital cardiopathy. It seems plausible that impaired
excretion, dissociation of the gadolinium chelate, and
prolonged tissue retention of gadolinium is a trigger for
NSF in patients with CKD. This risk increases with
cumulative dose of gadolinium, with decreasing GFR
<60 ml/min per 1.73 m
2, and in the presence of acidosis
and proinflammatory conditions. The scarcity of reported
children with NSF may well be due to the lower prevalence
of CKD and secondary conditions in children. It is therefore
imperative that paediatric practitioners are prudent and
immediately tighten their local policies for use of intrave-
nous gadolinium-based contrast agents.
It is difficult at present to suggest general guidelines,
because:
– The absolute risk of gadolinium exposure, as well as
the risk associated with the suspected contributing
clinical and biochemical factors, is unknown. Each case
must therefore be assessed individually.
– The risk attributable to the kinetic stability of different
gadolinium-based agents is not clear. The majority of
cases have been reported in association with a less
stable agent (gadodiamide); however, we are still in an
early stage of recording cases, and also the market
share and the actual use of different agents in this
patient population is not fully known. Thus, it seems
reasonable to discontinue the use of gadodiamide in at-
risk patients.
– The relationship to dose is not completely known.
Since there is no indication that we are dealing with a
side effect not related to dose, it seems reasonable to
reduce the dose of gadolinium if possible, and also to
monitor the cumulative dose in at-risk patients.
– It is unclear whether acidosis correction before gado-
linium administration and haemodialysis immediately
after gadolinium administration can prevent the devel-
opment of, or treat, NSF, but such actions should be
considered in children already on haemodialysis. This
underlines the necessity for good communication
between radiologists and nephrologists, both for issu-
ing local guidelines and for management of the
individual child.
It is often the case that MRI is requested after an
inconclusive US examination. In our own experience, more
meticulous patient preparation and dedicated rescanning of
the patient with US can often give diagnostically adequate
results. In patients with CKD not yet on dialysis CT is not a
desirable alternative due to ionizing radiation and the
nephrotoxicity of iodinated contrast agents. However, CT
may provide an option in patients who are already on
dialysis. MRI without intravenous contrast agent adminis-
tration has not yet been validated for vascular anatomy
prior to renal transplantation, but several techniques may be
valuable, such as 3-D-balanced steady-state free precession
imaging and time-of-flight angiography.
Patients with renal impairment may be referred for MRI
from non-nephrology units and a crucial question is how to
identify them. Our approach would be to include a
mandatory tick box on the referral form requiring the
referring clinician’s statement about renal function, and also
to include a question about any known renal problems on
the patient/guardian prescan checklist. This is a pragmatic
approach, which will need revision after an initial phase.
Conclusion
We would advocate prudence, and in practice suggest:
& Information collection from clinicians and patients/
guardians on renal dysfunction and active collaboration
with the local nephrology unit.
& A case-by-case assessment in terms of the necessity for
gadolinium-enhanced MRI, and whether an alternative
test (repeat US, noncontrast-enhanced MRI, CT) would
be acceptable.
& Cumulative dose recording, reduction of the dose of any
gadolinium-based contrast agent, and acting accordingly
to guidance published in the literature.
& Longer follow-up, especially in high-risk children.
& GFR measurement or estimation should be part of a
systematic prescan investigation in children with known
or suspected renal dysfunction; however, a general
screening is probably not justified.
& To minimize the risks, we should take advantage of
the current knowledge, and would suggest using cyclic
nonionic compounds as they are more stable in vitro
and therefore theoretically less likely to undergo
transmetallation.
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